The role of the tumour microenvironment in the angiogenesis of pituitary tumours
P Marques, S Barry, E Carlsen, D Collier, A Ronaldson… - Endocrine, 2020 - Springer
Purpose Angiogenesis has been studied in pituitary neuroendocrine tumours (PitNETs), but
the role of the tumour microenvironment (TME) in regulating PitNET angiogenesis remains …
the role of the tumour microenvironment (TME) in regulating PitNET angiogenesis remains …
Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma)
N Lenders, A McCormack - Pituitary, 2018 - Springer
Non-functioning pituitary carcinomas (NFPC) are defined as tumours of adenophyseal origin
with craniospinal or systemic dissemination, with the absence of a hormonal hypersecretion …
with craniospinal or systemic dissemination, with the absence of a hormonal hypersecretion …
Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy
MV Deligiorgi, G Siasos, C Vergadis… - International …, 2020 - Elsevier
Cancer immunotherapy is a breakthrough strategy entwined with toxicity. Immune-related
hypophysitis is conventionally considered distinctive of cytotoxic T-lymphocyte antigen 4 …
hypophysitis is conventionally considered distinctive of cytotoxic T-lymphocyte antigen 4 …
Temozolomide therapy for aggressive pituitary tumours–current understanding and future perspectives
P Burman, L Lamb, A McCormack - Reviews in Endocrine and Metabolic …, 2020 - Springer
The use of temozolomide (TMZ) for the management of aggressive pituitary tumours (APT)
has revolutionised clinical practice in this field with significantly improved clinical outcomes …
has revolutionised clinical practice in this field with significantly improved clinical outcomes …
The upregulation of molecules related to tumor immune escape in human pituitary adenomas
Z Xi, PS Jones, M Mikamoto, X Jiang, AT Faje… - Frontiers in …, 2021 - frontiersin.org
Human pituitary adenomas are one of the most common intracranial neoplasms. Although
most of these tumors are benign and can be treated medically or by transsphenoidal …
most of these tumors are benign and can be treated medically or by transsphenoidal …
The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor
D Nie, Q Fang, J Cheng, B Li, M Li, H Wang… - Cancer Immunology …, 2022 - Springer
Context Pituitary adenoma (PA) is a common intracranial tumor. The evidence indicates that
the tumor immune microenvironment (TIME) is associated with PA and that the intestinal …
the tumor immune microenvironment (TIME) is associated with PA and that the intestinal …
PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas
G Cossu, S La Rosa, JP Brouland, N Pitteloud, E Harel… - Cancers, 2023 - mdpi.com
Simple Summary The biological behavior of Pituitary Neuroendocrine Tumors (PitNET)
remains unclear. Many efforts have been performed in order to clarify this point. The …
remains unclear. Many efforts have been performed in order to clarify this point. The …
Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression
Y Mei, WL Bi, J Agolia, C Hu, AM Giantini Larsen… - Pituitary, 2021 - Springer
Purpose Pituitary tumors are the second most common primary brain tumors. Functional
tumors demonstrate increased PD-L1 expression, but expression of other checkpoint …
tumors demonstrate increased PD-L1 expression, but expression of other checkpoint …
Invited Review: Pathology of pituitary neuroendocrine tumours: present status, modern diagnostic approach, controversies and future perspectives from a …
E Manojlovic‐Gacic, J Bollerslev… - Neuropathology and …, 2020 - Wiley Online Library
Neuroendocrine tumours of the adenohypophysis have traditionally been designated as
pituitary adenomas to underline their usually indolent growth and lack of metastatic …
pituitary adenomas to underline their usually indolent growth and lack of metastatic …
Complete response of a patient with a mismatch repair deficient aggressive pituitary adenoma to immune checkpoint inhibitor therapy: a case report
S Shah, S Manzoor, Y Rothman, M Hagen, L Pater… - …, 2022 - journals.lww.com
CONCLUSION: APA is a tumor with frequent recurrence and a short median expected length
of survival. Here, we demonstrate the utility of immunotherapy in a single case report of APA …
of survival. Here, we demonstrate the utility of immunotherapy in a single case report of APA …